Navigation Links
Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
Date:2/16/2009

PITTSBURGH, Feb. 16 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, February 19, 2009, at 5:00 p.m. ET to review the company's financial results for the fourth quarter, which ended December 31, 2008. Mylan will release its financial results on February 19 after the market closes.

The dial-in number to access the February 19 call is 888-287-5536 or 719-325-2126 for international callers. A replay, available for approximately seven days, will be available at 888-203-1112 or 719-457-0820 for international callers with access pass code 4584157.

To access a live webcast of the February 19 call, please log on to Mylan's Web site (www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven days.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
2. Mylan Declares Quarterly Preferred Stock Dividend
3. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
4. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
5. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
6. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
8. Mylan Announces Move to NASDAQ Stock Market
9. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
10. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules
11. Mylan Receives Final Approval for First-to-File Generic Version of Antiepileptic Keppra(R) and Launches Immediately
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality ... problems, I focus on preventative care with all my patients to alleviate possible future issues. ... feel free to contact my office and my trained staff will assist you in any ...
(Date:4/25/2017)... ... ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will be featured ... publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is an Emergency ... He also serves as Medical Director for the Bureau of Emergency Medical Services and ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... Massachusetts (PRWEB) , ... April 24, 2017 , ... ... will help busy nursing professionals advance their careers. Beginning in the fall of 2017, ... Nursing (BSN) degree in as few as 16 months and for as little as ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... fiscal 2017 earnings per share (EPS) guidance and ... This is in conjunction with this morning,s announcement of ... Thrombosis and Nutritional Insufficiency businesses. Cardinal Health ... operations will be at the bottom of its previous ...
Breaking Medicine Technology: